ARE PLEASED TO ANNOUNCE THE WORLD FIRST MARKET AUTHORISATION FOR A DONOR-DERIVED MICROBIOME-BASED PRODUCT
Using the microbiome to treat disease
Who are you?
Unique ecosystem based approach to drug development
BiomeBank is on a mission to treat and prevent disease by restoring gut microbial ecology.
We are achieving this mission through the development and provision of microbial therapies that contain an extensive and diverse community of human gut microbes. These microbial consortia treat disease by repopulating wide range of missing microbes and restoring lost function.
Our team of translational microbiome experts have developed a unique drug discovery platform that combines the capabilities of advanced bioinformatic analysis with phenotypic microbiology to inform microbiome drug discovery and development.
BiomeBank’s donor derived first generation microbiome therapy was the first such therapy approved world-wide and is used to treat patients with C.difficile throughout Australia. Our second generation, cultured therapies consist of a diverse microbial ecosystem enriched for microbes carrying disease specific functions. These therapies are in development for a number of disease indications and will enter human trials in 2023 for the treatment of Ulcerative Colitis.
BiomeBank's pioneering research has been published in these leading medical journals:
Latest news
Long reads
Get a better understanding of your microbiome with our long read articles.
BiomeBank has been featured by:
The gut microbiome is the community of organisms that live in your intestinal tract. In fact, trillions of microbes call the human gut home. Although one single microbe is harmless, vast communities of different species together carry important functions for maintaining health, similar to an organ. Loss of function can lead to chronic disease.
In recent years new technology has enabled scientists to culture and analyse the DNA of these complex communities. This has paved the way for new breakthroughs in the treatment of chronic disease where the traditional approach of drugs and surgeries are proving inadequate.
We are a multidisciplinary team of research scientists and drug development experts who are at the forefront of microbiome research, looking to discover and develop microbiome-based therapies.
The translation of research into the development of innovative and life-saving microbiome-based therapies are further bolstered by BiomeBank’s partnership with world-leading biomedical research organisations. This includes RMIT University, Hudson Institute of Medical Research, and Hospital Networks globally.